Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 10/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 9/20 | 1.00 |
| ▸ | TUBB | P07437 | 9/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 9/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 9/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 9/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 9/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 9/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 9/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 9/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 9/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 9/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 9/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 9/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 9/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Combretastatin SCHEMBL30334938 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL29356562 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL19955 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL19956 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL5566666 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6430099 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6429581 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6430650 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6429578 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6429821 | 0.98 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3868409-B1 | THIOPHENOL-MALEIMIDE AND BROM-MALEIMIDE DERIVATIVES AS LINKER FOR ANTIBODY-DRUG CONJUGATES (ADC) FOR TREATING TUMORS | REMEGEN CO LTD (CN) | 2024-07-17 | — | — | EP | claimed |
| EP-4110405-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | MCSAF INSIDE ONOCOLOGY (FR) | 2023-01-04 | — | — | EP | claimed |
| EP-3972652-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | Mc SAF (FR) | 2022-03-30 | — | — | EP | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007755-A1 | SELF-ASSEMBLED DIBLOCK COPOLYMERS COMPOSED OF PEGMEMA AND DRUG BEARING POLYMERIC SEGMENTS | RS ARASTIRMA EGITIM DANISMANLIK ILAC SANAYI TICARET ANONIM SIRKETI (TR) | 2026-01-08 | — | — | US | disclosed |
| WO-2025245128-A1 | ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | MYTHIC THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4401787-B1 | VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE | CENTRE NAT RECH SCIENT (FR) | 2025-11-05 | — | — | EP | disclosed |
| EP-4630456-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | Mythic Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250223554-A1 | METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR CANCER THERAPY | RENOVARO BIOPHARMA INC. | 2025-07-10 | — | — | US | disclosed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2025-05-08 | — | — | US | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-4003428-A1 | ANTIBODY-POLYMER-CONJUGATES | Bogazici Universitesi (TR) | 2022-06-01 | — | — | EP | disclosed |
| US-20220152216-A1 | ANTIBODY-POLYMER CONJUGATES | BOGAZICI UNIVERSITESI (TR) | 2022-05-19 | — | — | US | disclosed |
| US-20220127308-A1 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-11311625-B2 | Peptide-based multiple-drug delivery vehicle | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2022-04-26 | — | — | US | disclosed |
| US-11291630-B2 | Gelling compositions for treating malignant tumours and/or preventing tumour recurrence | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2022-04-05 | — | — | US | disclosed |
| EP-3972652-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | Mc SAF (FR) | 2022-03-30 | — | — | EP | disclosed |
| CN-114206885-A | Pyrazolo [3,4-B ] pyrazine SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-11248028-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007755-A1 | SELF-ASSEMBLED DIBLOCK COPOLYMERS COMPOSED OF PEGMEMA AND DRUG BEARING POLYMERIC SEGMENTS | CLTB, F13B, FGB | TUBB1 231/4885TUBB4A 310/4885TUBB 178/4885 |
| US-11311625-B2 | Peptide-based multiple-drug delivery vehicle | VIP, NGLY1, IAPP | TUBB1 1753/4885TUBB4A 1770/4885TUBB 1357/4885 |
| US-20220152216-A1 | ANTIBODY-POLYMER CONJUGATES | CD44, FCGR1A, FCGR2A | TUBB1 479/4885TUBB4A 491/4885TUBB 650/4885 |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | CDK9, BCL9, CDK19 | TUBB1 2062/4885TUBB4A 1658/4885TUBB 1741/4885 |
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | TUBB1 621/4885TUBB4A 982/4885TUBB 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.